Clene price target raised to $50 from $48 at Canaccord

Canaccord raised the firm’s price target on Clene (CLNN) to $50 from $48 and keeps a Buy rating on the shares. The firm noted the company recently announced that it plans to file a new drug application (NDA) with the FDA in 3Q26 for CNM-Au8 (nanocrystalline gold) for amyotrophic lateral sclerosis (ALS) under the accelerated approval pathway. Canaccord believes the shares are undervalued for a company close to filing in a high unmet need indication.